EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 6-7 (Juin-Juillet 2004) Med Sci (Paris), 20 6-7 (2004) 701-706 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 6-7, Juin-Juillet 2004
Page(s) 701 - 706
Section Dossier technique
DOI https://doi.org/10.1051/medsci/2004206-7701
Published online 15 June 2004
  1. Reichel E, Berrocal A, Ip M, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999; 106 : 1908–14. [Google Scholar]
  2. Schmidt-Refurth U, Miller J, Sickenberg M, et al. Photodynamic therapy with verteprofin for choroidal neovascularization cauzed by age-related macular degeneration. Arch Ophthalmol 1999; 117 : 1177–87. [Google Scholar]
  3. Hauswirth WW, Lewin AS. Ribozyme uses in retinal gene therapy. Prog Retin Eye Res 2000; 19 : 689–710. [Google Scholar]
  4. Acland GM, Aguire GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001; 28 : 92–5. [Google Scholar]
  5. Liang FQ, Dejneka NS, Cohen DR, et al. Aav-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol Ther 2001; 3 : 241–8. [Google Scholar]
  6. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nature Med 1999; 5 : 1359–64. [Google Scholar]
  7. Nir I, Kedzierski W, Chen J, Travis GH. Expression of Bcl-2 protects against photoreceptor degeneration in retinal degeneration slow (rds) mice. J Neurosci 2000; 15 : 2150–4. [Google Scholar]
  8. Frasson M, Sahel JA, Fabre M, et al. Retinitis pigmentosa : Rod photoreceptor rescue by a calcium-channel blocker in the rd mouse. Nature Med 1999; 5 : 1183–7. [Google Scholar]
  9. Maurice D, Mishima S. Ocular pharmacokinetics in ML. In : Sears ML, ed. Pharmacology of the eye. Berlin : Springer-Verlag, 1984 : 19–116. [Google Scholar]
  10. Tojo K, Isowaki A. Pharmacokinetic model for in vivo/in vitro correlation of intravitreal drug delivery. Advanced Drug Delivery Rev 2001; 52 : 17–24. [Google Scholar]
  11. Weijtens O, van der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroids injection : Vitreal and serum concentrations after dexamethasone disodium phosphate injection. Am J Ophthalmol 1997; 123 : 358–63. [Google Scholar]
  12. Bodker FS, Ticho BH, Feist RM, Lam TT. Intraocular dexamethasone penetration via subconjunctival or retrobulbar injections in rabbits. Ophthalmic Surg 1993; 24 : 453–7. [Google Scholar]
  13. Blair NP, Evans MA, Lesar TS, Zeimer RC. Fluorescein and fluorescein glucuronide pharmacokinetics after intravenous injection. Invest Ophthalmol Vis Sci 1986; 27 : 1107–14. [Google Scholar]
  14. Araie M, Maurice DM. The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextran from the vitreous by the anterior and retinal pathways. Exp Eye Res 1991; 52 : 27–39. [Google Scholar]
  15. Martin DF, Parks DJ, Mellow SD, et al. Treatment of CMV retinitis with an intraocular sustained-release ganciclovir implant : A randomized controlled clinical trial. Arch Ophthalmol 1994; 112 : 1531–9. [Google Scholar]
  16. Jaffe G, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 2000; 11 : 2024–33. [Google Scholar]
  17. Kimura H, Ogura Y, Hashizoe M, et al. A new vitreal drug delivery system using an implantable biodegradable polymeric device. Invest Ophthalmol Vis Sci 1994; 35 : 2815–9. [Google Scholar]
  18. Kunou N, Ogura Y, Yasukawa T, et al. Long term sustained release of GC from biodegradable scleral implant for the treatment of CMV retinitis. J Control Release 2000; 10 : 263–71. [Google Scholar]
  19. Hashizoe M, Ogura Y, Takanashi T, et al. Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Curr Eye Res 1995; 14 : 473–7. [Google Scholar]
  20. Kunou N, Ogura Y, Honda Y, et al. Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate. Int J Biomat Res 2000; 51 : 634–41. [Google Scholar]
  21. Peyman GA, Yang D, Khoobehi B, et al. In vitro evaluation of polymeric matrix and porous biodegradable reservoir devices for slow-release drug delivery. Ophthalmic Surg and lasers 1996; 27 : 384–91. [Google Scholar]
  22. Chasin M, Domb A, Ron E, et al. Polyanhydrides as drug delivery systems. In : Chasin M, Langer R, eds. Biodegradable polymers as drug delivery systems. New York : Marcel Dekker, 1990 : 43–70. [Google Scholar]
  23. Heller J, Barr J, Shen H, et al. Poly(ortho esters)-their development and some recent applications. Eur J Pharm Biopharm 2000; 50 : 121–8. [Google Scholar]
  24. Behar-Cohen F, BenEzra D, Einmahl S, Gurny R. Challenge of intraocular dug delivery. Eur J Pharm Rev 2001; 6 : 35–40. [Google Scholar]
  25. Einmahl S, Capancioni S, Schwach-Abdellaoui K, et al. Therapeutic applications of viscous and injectable poly(ortho) esters. Adv Drug Deliv Rev 2001; 53 : 45–73. [Google Scholar]
  26. Einmahl S, Behar-Cohen F, Tabatabay C, et al. A viscous bioerodible poly(ortho ester) as a new biomaterial for intraocular application. J Biomed Mater Res 2000; 5 : 566–73. [Google Scholar]
  27. Einmahl S, Behar-Cohen F, D’Hermies F, et al. A new poly(ortho ester)-based drug delivery system for the adjunct treatment of filtering surgery. Invest Ophthalmol Vis Sci 2000; 42 : 695–700. [Google Scholar]
  28. Einmahl S, Savoldelli M, D’Hermies F, et al. Evaluation of a new biomaterial in the suprachoroidal space. Invest Ophthalmol Vis Sci 2002; 43 : 1533–9. [Google Scholar]
  29. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreous kinetics. Ophthalmic Res 2001; 33 : 31–6. [Google Scholar]
  30. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactides nanoparticles. Invest Ophthalmol Vis Sci 2003; 44 : 3562–9. [Google Scholar]
  31. Peyman G, Convay M, Khoobei B, Soike K. Clearance of of microsphere-entrapped 5-FU and cytosine arabinoside from the vitreous of primate. Int Ophthalmol 1992; 16 : 109–13. [Google Scholar]
  32. Moritera T, Ogura Y, Yoshimura N, et al. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreo retinopathy. Invest Ophthalmol Vis Sci 1992; 33 : 3125–30. [Google Scholar]
  33. Akula SK, Ma PE, Peyman GA, et al. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br J Ophthalmol 1994; 78 : 677–80. [Google Scholar]
  34. Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 2002; 43 : 253–9. [Google Scholar]
  35. Barza M, Stuart M, Szoka F, Jr. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci 1987; 28 : 893–900. [Google Scholar]
  36. Ambati J, Canakis CS, Miller JW, et al. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci 2000; 41 : 1181–5. [Google Scholar]
  37. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001; 52 : 37–48. [Google Scholar]
  38. Ambati J, Gragoudas ES, Miller JW, et al. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci 2000; 41 : 1186–91. [Google Scholar]
  39. Behar-Cohen F, Parel JM, El Aouni A, Chauvaud D. Iontophoresis : The past and the future. J Fr Ophthalmol 2001; 24 : 319–27. [Google Scholar]
  40. Voigt M, de Kozak Y, Halhal M, et al. Down regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis. Biochem Biophys Res Comm 2002; 295 : 336–41. [Google Scholar]
  41. Lam TT, Fu J, Tso MO. A histopathological study of retinal lesions inflicted by transscleral iontophoresis Graefe’s Arch Clin Exp Ophthalmol 1991; 229 : 389–94. [Google Scholar]
  42. Behar-Cohen FF, El Aouni A, Gautier S, et al. Transscleral coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye : Influence of duration of treatment, current intensity and drug concentration in ocular tissues and fluids levels. Exp Eye Res 2002; 74 : 51–9. [Google Scholar]
  43. Halhal M, Renard G, Courtois Y, et al. Iontophoresis from the lab to the bedside. Exp Eye Res 2004; 78 : 751–7. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.